The authors evaluate the effect of various mill types on particle-size distribution, flowability, tabletability, and compactibility. The particle-size distribution of a pharmaceutical granulation is ...

Although physicochemical preformulation screening is practised universally within the pharmaceutical industry, physicomechanical screening is applied to a lesser extent and often only where a problem ...

When selecting the appropriate formulation of Livmarli, the patient's weight and ability to swallow tablets should be considered. Livmarli tablets are supplied in 10mg, 15mg, 20mg, and 30mg dosage ...

Credit: Genentech. The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water. Each Evrysdi tablet contains 5mg of risdiplam and is suitable ...

In the evolving landscape of pharmaceutical development, modified release (MR) tablets have emerged as a cornerstone technology for improving therapeutic outcomes and patient compliance. Unlike ...

New formulation provides patients with a simplified dosing experience—reducing pill burden and enhancing ease of administration—while preserving flexible dosing options SAN CARLOS, Calif., June 11, ...

Iron tablets come in various formulations like ferrous sulfate, ferrous fumarate, ferrous gluconate, ferrous ascorbate, and ferrous bisglycinate. These supplements meet different needs for treating ...

BASEL, Switzerland--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...

The FDA approved a new tablet formulation of Brukinsa for five cancer indications, simplifying dosing to two 160 mg tablets daily. Brukinsa is the only BTK inhibitor offering flexible dosing and ...

The European Medicines Agency’s human medicines committee has recommended approval of a new tablet formulation of BeOne Medicines’ targeted blood cancer drug Brukinsa (zanubrutinib). The company ...

MIAMI - Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced Friday positive pharmacokinetic (PK) data from its ongoing Phase 1/1b study of PAS-004 tablet formulation in adult patients with ...

FOSTER CITY, Calif., April 14, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation ...